Is Avanos Medical (AVNS) overvalued or fairly valued?

MarketChacha shows Avanos Medical's valuation in context — a forward P/E of about 20.0, a price-to-book of about 1.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Avanos Medical's revenue?

Avanos Medical reported revenue of $701.2M for FY2025, with net profit of $-72.9M, per official filings.

What is the share price of Avanos Medical (AVNS)?

Avanos Medical last traded at $24.99 (+0.0% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Avanos Medical

AVNS · NYSE · Healthcare · United States

$24.99+0.0%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:30 PM

Snapshot

TickerAVNS

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees2,287

HeadquartersAlpharetta, United States

Market cap$1.2B

P/B1.5

Volume223.78K

Websiteavanos.com

Filings tracked5

About Avanos Medical

Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; and Trident and Esentec RFA radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. Avanos Medical, Inc. was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. The company was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Profile as reported by Yahoo Finance.

Who owns it

Insiders3.3%
Institutions92.6%
Public & other4.1%

359 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.14.61%
T. Rowe Price Investment Management, Inc.11.38%
Brown Advisory Inc.4.76%
Dimensional Fund Advisors LP4.38%
Armistice Capital, LLC4.27%
Vanguard Capital Management LLC4.21%
State Street Corporation4.21%
Vanguard Portfolio Management LLC2.65%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Latest ROE of -9.4% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-9.2% → -10.4%

Margin has held broadly steady over the period — stable profitability.

Return on equity-9.4%

Latest ROE of -9.4% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $181.0M · EPS 0.33

Est. earnings growth +50.0%

Next fiscal year

Rev $740.0M · EPS 1.25

Est. earnings growth +25.0%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$9.3052-wk range$25.49

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.2B

Day change

+0.0%

Fwd P/E

20.0

P/B

1.5

Beta

1.57

Revenue (FY2025)

$701.2M

Net margin

-10.4%

ROE

-9.4%

Revenue CAGR (2y)

+2.1%

EPS (FY2025)

-1.57

Net profit (FY2025)

$-72.9M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about AVNS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$701.2M	$-72.9M	-1.57	-10.4%	-9.4%
FY2024	$687.8M	$-392.1M	-8.53	-57.0%	-47.3%
FY2023	$673.3M	$-61.8M	-1.32	-9.2%	-5.0%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$182.2M	$5.1M	0.11	2.8%
2025Q3	$177.8M	$-1.4M	-0.03	-0.8%
2025Q2	$175.0M	$-76.8M	-1.66	-43.9%
2025Q1	$167.5M	$6.6M	0.14	3.9%
2024Q3	$170.4M	$4.3M	0.09	2.5%
2024Q2	$171.7M	$1.8M	0.04	1.0%
2024Q1	$166.1M	$-900,000	-0.02	-0.5%
2023Q3	$171.3M	$-3.7M	-0.08	-2.2%
2023Q2	$169.4M	$-68.1M	-1.46	-40.2%
2023Q1	$159.3M	$-500,000	-0.01	-0.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Other events, Exhibits
SEC7/15/2026material
8-K — Reg FD disclosure, Exhibits
SEC7/2/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K — Material agreement, Reg FD disclosure, Exhibits
SEC4/14/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.